MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下「ノバルティス ファーマ」）は本日、「ファビハルタ ® カプセル200mg」（一般名 ...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in ...
About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing ...
PSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination with standard of care (ADT + ARPI) vs. SoC alone, with positive overall survival trend (HR=0.80) ...
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, ...
For World Sjögren's Day, dancer and TV personality Carrie Ann Inaba shares her story of diagnosis, living with the disease, and self-advocacy Every fall, millions of viewers watch Carrie Ann Inaba ...
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs 1 Clinically relevant 15.2% ...
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results